These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34665694)

  • 1. Sustained erythrocytosis due to the use of Lenvatinib.
    Kaur J; Tuler S; Dasanu CA
    J Oncol Pharm Pract; 2022 Mar; 28(2):475-478. PubMed ID: 34665694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer.
    Koehler VF; Berg E; Adam P; Weber GL; Pfestroff A; Luster M; Kutsch JM; Lapa C; Sandner B; Rayes N; Fuss CT; Kreissl MC; Hoster E; Allelein S; Schott M; Todica A; Fassnacht M; Kroiss M; Spitzweg C
    Thyroid; 2021 Oct; 31(10):1531-1541. PubMed ID: 34405734
    [No Abstract]   [Full Text] [Related]  

  • 3. Progressive erythrocytosis under lenvatinib treatment in patients with advanced hepatocellular carcinoma.
    Legros L; Pascale A; Guettier C; Eftekhari P; Merabet YB; Stang M; Bossevot R; Goldschmidt E; Ulusakarya A; Morisset S; Lewin M; Samuel D; Rosmorduc O
    Cancer Chemother Pharmacol; 2023 Apr; 91(4):337-344. PubMed ID: 36961524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenvatinib-Associated Erythrocytosis.
    Lakra R; Grewal US; Beedupalli K
    Am J Ther; 2024 Mar-Apr 01; 31(2):e201-e203. PubMed ID: 36989234
    [No Abstract]   [Full Text] [Related]  

  • 5. Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report.
    Furuto Y; Hashimoto H; Namikawa A; Outi H; Takahashi H; Horiuti H; Honda K; Shibuya Y
    BMC Nephrol; 2018 Oct; 19(1):273. PubMed ID: 30340546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria.
    Goto H; Kiyota N; Otsuki N; Imamura Y; Chayahara N; Suto H; Nagatani Y; Toyoda M; Mukohara T; Nibu KI; Kasahara T; Ito Y; Miya A; Hirokawa M; Miyauchi A; Minami H
    Auris Nasus Larynx; 2018 Dec; 45(6):1249-1252. PubMed ID: 29779695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem.
    Nervo A; Ragni A; Gallo M; Ferraris A; Fonio P; Piovesan A; Arvat E
    Thyroid; 2020 Feb; 30(2):229-236. PubMed ID: 31854230
    [No Abstract]   [Full Text] [Related]  

  • 8. Pazopanib-related secondary polycythemia in metastatic myxofibrosarcoma: A case report and review of the literature.
    Fanelli M; Caputo F; Cerma K; Gelsomino F; Bari A; Dominici M; Pozzi S
    J Oncol Pharm Pract; 2021 Apr; 27(3):766-770. PubMed ID: 32838682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Anaplastic Thyroid Carcinoma.
    Osawa Y; Gozawa R; Koyama K; Nakayama T; Sagoh T; Sunaga H
    Intern Med; 2018 Apr; 57(7):1015-1019. PubMed ID: 29225265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer.
    Giani C; Valerio L; Bongiovanni A; Durante C; Grani G; Ibrahim T; Mariotti S; Massa M; Pani F; Pellegriti G; Porcelli T; Salvatore D; Tavarelli M; Torlontano M; Locati L; Molinaro E; Elisei R
    Thyroid; 2021 Feb; 31(2):224-232. PubMed ID: 32907501
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term efficacy of lenvatinib for recurrent papillary thyroid carcinoma after multimodal treatment and management of complications: a case report.
    Tori M; Shimo T
    BMC Cancer; 2018 Jun; 18(1):698. PubMed ID: 29954369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between toxicities and clinical benefits of newly approved tyrosine kinase inhibitors in thyroid cancer: A meta-analysis of literature.
    Ye X; Zhu Y; Cai J
    J Cancer Res Ther; 2015 Oct; 11 Suppl 2():C185-90. PubMed ID: 26506873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.
    Wilson L; Huang W; Chen L; Ting J; Cao V
    Thyroid; 2017 Aug; 27(8):1043-1052. PubMed ID: 28486081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer.
    Nagahama M; Ozeki T; Suzuki A; Sugino K; Niioka T; Ito K; Miura M
    Med Oncol; 2019 Mar; 36(5):39. PubMed ID: 30919115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer.
    Cabanillas ME; Takahashi S
    Semin Oncol; 2019 Feb; 46(1):57-64. PubMed ID: 30685073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
    Wirth LJ; Tahara M; Robinson B; Francis S; Brose MS; Habra MA; Newbold K; Kiyota N; Dutcus CE; Mathias E; Guo M; Sherman SI; Schlumberger M
    Cancer; 2018 Jun; 124(11):2365-2372. PubMed ID: 29656442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal perforation related to lenvatinib, an anti-angiogenic inhibitor that targets multiple receptor tyrosine kinases, in a patient with metastatic thyroid cancer.
    Date E; Okamoto K; Fumita S; Kaneda H
    Invest New Drugs; 2018 Apr; 36(2):350-353. PubMed ID: 29018997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer.
    Brose MS; Panaseykin Y; Konda B; de la Fouchardiere C; Hughes BGM; Gianoukakis AG; Joo Park Y; Romanov I; Krzyzanowska MK; Leboulleux S; Binder TA; Dutcus C; Xie R; Taylor MH
    J Clin Endocrinol Metab; 2022 Feb; 107(3):776-787. PubMed ID: 34664662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cortisol Deficiency in Lenvatinib Treatment of Thyroid Cancer: An Underestimated Common Adverse Event.
    Monti S; Presciuttini F; Deiana MG; Motta C; Mori F; Renzelli V; Stigliano A; Toscano V; Pugliese G; Poggi M
    Thyroid; 2022 Jan; 32(1):46-53. PubMed ID: 34663079
    [No Abstract]   [Full Text] [Related]  

  • 20. Lenvatinib in Advanced Radioiodine-refractory Thyroid Cancer: A Snapshot of Real-life Clinical Practice.
    Nervo A; Gallo M; Samà MT; Felicetti F; Alfano M; Migliore E; Marchisio F; Berardelli R; Arvat E; Piovesan A
    Anticancer Res; 2018 Mar; 38(3):1643-1649. PubMed ID: 29491097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.